AzurRx BioPharma Inc

-0.01 (-1.42%)

AzurRx Biopharma Requests Protocol Amendment To Phase 2b OPTION 2 Study Of MS1819 In Cystic Fibrosis Patients

Published: 11/17/2020 13:20 GMT
AzurRx BioPharma Inc (AZRX) - Azurrx Biopharma Requests Protocol Amendment to Phase 2b Option 2 Study of Ms1819 in Cystic Fibrosis Patients.
Azurrx Biopharma - Intention is to Identify Optimal Delivery Method and Potentially Provide Additional Scientific Support and Optionality for Ms1819.
Azurrx Biopharma Inc - Remain on Target to Release Top Line Data in Q1 of 2021.